Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials

• Type: Another Publication in an International Scientific Journal
• Date: 2020

Authors

Silva Cardoso, J (Author) FMUP; Sheikh, O (Author) Other; Nashawi, M (Author) Other; Pham, S (Author) Other; Gallegos, KM (Author) Other; Dinkha, LR (Author) Other; Chilton, RJ (Author) Other

Journal

Title: Journal of Diabetes

Vol. 12

Pages: 279-293

ISSN: 1753-0393

Publisher: Wiley-Blackwell

Indexing

ISI Web of Knowledge - 6 Citations

Other information

Authenticus ID: P-00S-0QW

DOI: 10.1111/1753-0407.13007

Abstract (EN): Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs that were primarily developed for the treatment of type 2 diabetes mellitus. However, these agents have shown to provide additional beneficial effects. We will discuss three main topics regarding the use of SGLT2 inhibitors: noncardiovascular effects, cardiovascular benefits, and novel clinical indications. Multiple clinical trials and preliminary studies across varying disciplines have shown that these agents exhibit cardiorenal-protective benefits, retinoprotective benefits, and may aid in weight loss without causing marked hypoglycemia. Therefore, these agents represent an avenue in clinical practice to manage comorbid conditions in the hyperglycemic patient. Because of their multifaceted effects and robust action, SGLT2 inhibitors represent therapy options for providers that not only provide beneficial clinical results but also reduce total patient drug burden.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 15